New hope for rare kidney cancer: targeted drug savolitinib faces off against standard therapy
NCT ID NCT03091192
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This phase 3 study compares a new drug, savolitinib, to the standard drug sunitinib in 60 people with a specific type of advanced kidney cancer called MET-driven papillary renal cell carcinoma. The goal is to see if savolitinib is better at stopping the cancer from growing and to check its side effects. Participants take one of the two pills by mouth daily.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
La Jolla, California, 92093, United States
-
Research Site
Atlanta, Georgia, 30322, United States
-
Research Site
Chicago, Illinois, 60637, United States
-
Research Site
Iowa City, Iowa, 52242, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
Kansas City, Missouri, 64132, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Barretos, 14784-400, Brazil
-
Research Site
Curitiba, 81520-060, Brazil
-
Research Site
Passo Fundo, 99010-080, Brazil
-
Research Site
Pelotas, 096015-280, Brazil
-
Research Site
Porto Alegre, 90050-170, Brazil
-
Research Site
Porto Alegre, 90610-000, Brazil
-
Research Site
Porto Alegre, 91350-200, Brazil
-
Research Site
Rio de Janeiro, 22793-080, Brazil
-
Research Site
São José do Rio Preto, 15090-000, Brazil
-
Research Site
São Paulo, 01246-000, Brazil
-
Research Site
São Paulo, 01323-903, Brazil
-
Research Site
Bordeaux, 33000, France
-
Research Site
Vandœuvre-lès-Nancy, 54519, France
-
Research Site
Villejuif, 94805, France
-
Research Site
Arezzo, 52100, Italy
-
Research Site
Meldola, 47014, Italy
-
Research Site
Milan, 20133, Italy
-
Research Site
Modena, 41100, Italy
-
Research Site
Orbassano, 10043, Italy
-
Research Site
Pavia, 27100, Italy
-
Research Site
Roma, 00152, Italy
-
Research Site
Krasnoyarsk, 660133, Russia
-
Research Site
Moscow, 105077, Russia
-
Research Site
Moscow, 115478, Russia
-
Research Site
Moscow, 115522, Russia
-
Research Site
Moscow, RU-121356, Russia
-
Research Site
Murmansk, 183047, Russia
-
Research Site
Nizhny Novgorod, 603109, Russia
-
Research Site
Obninsk, 249036, Russia
-
Research Site
Omsk, 644013, Russia
-
Research Site
Saint Petersburg, 194017, Russia
-
Research Site
Saint Petersburg, 195271, Russia
-
Research Site
Saint Petersburg, 196603, Russia
-
Research Site
Volgograd, 400138, Russia
-
Research Site
Daejeon, 35015, South Korea
-
Research Site
Goyang-si, 10408, South Korea
-
Research Site
Hwasun-gun, 58128, South Korea
-
Research Site
Incheon, 21565, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06273, South Korea
-
Research Site
Seoul, 120-752, South Korea
-
Research Site
Seoul, 6351, South Korea
-
Research Site
Dnipro, 49005, Ukraine
-
Research Site
Dnipro, 49102, Ukraine
-
Research Site
Ivano-Frankivsk, 76018, Ukraine
-
Research Site
Kharkiv Region, 61070, Ukraine
-
Research Site
Kyiv, 03022, Ukraine
-
Research Site
Kyiv, 03115, Ukraine
-
Research Site
Odesa, 65055, Ukraine
-
Research Site
Sumy, 40022, Ukraine
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
savolitinib
What this could lead to
If it works, this could provide a more effective treatment option for people with a specific type of kidney cancer that has spread.
What could go wrong
This is a phase 3 trial, but it's small (60 people) and results may not apply to all patients. Savolitinib may not prove better than sunitinib and could have unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.